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Retinoic acid (RA), the active form of vitamin A, induces neuroblastoma cells SH-SY5Y to differentiate. In addition to its classical transcriptional actions regulating the expression of 
specific genes, RA acts in an extra-genomic way, modulating the activity of relevant signalling cascades. In particular, RA treatment of SH-SY5Y neuroblastoma cells results in activation 
of phosphatidyl-inositol-3-kinase (PI3K) signaling pathway, and this activation is required for RA-induced differentiation (Lopez-Carballo G. et al., J. Biol. Chem. 277, 25297-25304, 2002). 
RA activates PI3K and also ERK1/2 MAP Kinase signaling pathways through a rapid, non-genomic mechanism that does not require new gene transcription or newly synthesized 
proteins. Activation of PI3K by RA appears to involve the classical nuclear receptor RAR, on the basis of the pharmacological profile of the activation, loss and gain of function 
experiments with MEF-RAR(αβγ)L-/L- null cells, and the physical association between liganded RAR and PI3K kinase activity. Immunoprecipitation experiments performed in SH-SY5Y 
cells showed stable association between RARα and p85, the regulatory subunit of PI3K, independently of the presence of RA. In contrast, ligand administration increased the 
association of p110, the catalytic subunit of PI3K, to this complex. The intracellular localization of RAR resulted to be relevant for PI3K activation. A chimerical RAR receptor fusing c-Src 
myristylation domain to the N-terminal of RARα (Myr-RARα) was targeted to plasma membrane. Transfection of Myr-RARα to MEF-RAR(αβγ)L-/L-  null cells and COS-7 cells results in 
strong activation of PI3K signalling pathway. Our results suggest a mechanism in which ligand binding to RAR would play a major role in the assembly and intracellular location of a 
signalling complex involving RAR and the subunits of PI3K( Masiá S. et al., Mol. Endrocinol., in press, 2007).  
Next, we have investigated the consequences of the activation of signalling pathways by RA in neuroblastoma cells. Western blots using an antibody which specifically recognizes the 
phosphorylation motif of Akt have demonstrated that Akt activation in response to RA treatment produced a rapid phosphorylation of downstream substrates. Moreover, RA treatment 
resulted in rapid phosphorylation of well-known targets of Akt, such as mTOR and the ribosomal kinase p70S6, and other proteins, as CREB and histone H3, which are likely targets of 
RA non-genomic actions according to the scientific literature. In a second approach, nuclear phospho-proteins from control and RA-treated neuroblastoma cells were purified by affinity 
chromatography and analysed by 2D-electrophoresis. The differentially expressed spots were identified by Mass Spectrometry. We have found that RA treatment induces 
phosphorylation of chromatin proteins (HMGB1 and Histone H1.5) and proteins involved in the processing and transport of mRNA (PABP, hnRNP-K, hnRNP-C1/C2, Nucleophosmin). 
Finally, the observed RA-induced phosphorylation changes in these proteins were confirmed in 2-D western blots and immunoprecipitation experiments. 
Activation of PI3K/Akt signalling by RA in SH-SY5Y neuroblastoma cells is rapid (within 5 min. of 
treatment) (Fig. 1A), and did not required newly synthesized proteins or newly transcribed genes (Fig. 1B). 
This suggests that activation of PI3K/Akt by RA occurs through an atypical non-genomic mechanism. 
Involvement of the Nuclear Receptor RAR in the activation of PI3K/Akt is supported by loss and gain of 
function experiments with MEF-RAR(αβγ)L-/L- cells. RAR null cells have lost the ability of activating 
PI3K/Akt signalling (Fig. 1D), as compared with MEF-wt cells (Fig. 1C). Activation of PI3K/Akt by RA could 
be restored by expressing a functional RARα (Fig. 1E). 
A stable association between RARα and the regulatory subunit of PI3K, p85, which was not affected by the 
administration of RA, could be detected in SH-SY5Y neuroblastoma cells by immunoprecipitation (Fig. 1F 
and 1H). That complex could be immunoprecipitated from nuclear extracts (Fig. 1G). However, association 
of the catalytic subunit p110-PI3K to that complex  depends on the administration of RA (Fig. 1F and Fig. 
1I), suggesting that activation of RARα by its cognate ligand results in the formation of a signalling 
complex including RARα , and the regulatory and catalytic subunits of PI3K. 
F 
1. Rapid, non-genomic activation of PI3K/AKT by RA is 
mediated by its nuclear receptor RAR and  involves the 
association between RARα and PI3K subunits  
ACKNOWLEDGEMENTS: Supported by grants SAF2003-00311 and SAF2006-00647 from 
D. G. Investigación (MEC, Spain). E. J. Laserna was supported by a FPI fellowship from 
Generalitat Valenciana. S. Masiá was supported by a FPI fellowship (MEC) and a training 
contract from Programa de Personal Técnico de Apoyo (MEC/Fondo Social Europeo).  
4. Proteomic strategy to identify changes in the 
phosphorylation of nuclear proteins 
Control RA (1µM, 30 min) 
NUCLEAR EXTRACT 
Phospho-protein enriched fraction 
SH-SY5Y Cells 
“Wash”/dialysis with Nanosep 
Affinity chromatography 
(Qiagen phosphoprotein 
purification kit) 
Bioinformatic analysis 
(PD-Quest) 
Identify diferential spots 
Mass Spectrometry 
analysis 
2D- electro-
phoresis 
IEF 
SDS 
Spot 
Number 
Identified protein Sequenced peptides Score 
E-value 
in BLAST 
Coverage 
(%) 
MW 
(KDa) 
pI 
1 Nucleophosmin MSVQPTVSLGGFEITPPVVLR 
DELHIVEAEAMNYEGSPIK 
45,1 
4x10-5 
13,6 % 29-32 4,5 
2 and 10 Histone H1.5 KATGPPVSELITK 
ERNGLSLAALK 
ALAAGGYDVEKNNSR 
SLVSKGTLVQTK 
GTGASGSFKLNK 
KAASGEAKPK 
AKKPAGATPK 
KPAAAGVKK 
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5x10-14 
41 % 22 10,9 
3 and  4 HMGB1 GKMSSYAFFVQTCR 
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6 and 7 HnRNP-C1/C2 MIAGQVLDINLAAEPK 
GFAFVQYVNER 
34,3 
0,062 
8,8 % 39-41 4,95 
8 HnRNP-K NLPLPPPPPPR 
ILSISADIETIGEILKK 
IILDLISESPIK 
39,3 
0,002 
7,1 % 65 5,4 
9 PABP2 GFAYIEFSDKESVR 
TSLALDESLFR 
51,6 
4x10-7 
5,7 % 50 5,2 
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To identify the targets of RA-induced phosphorylation in the nucleus, we have set a proteomic approach 
(outlined in Fig. 4A), combining affinity purification of phosphoproteins, 2D-electrophoretic separation, and 
bioinformatic analysis to the selection of the spots differentially represented (Fig. 4B). Spots 1 to 8 were over-
expressed, spot 9 was under-expressed and spot 10 underwent a horizontal displacement. These spots were 
extracted and identified by mass spectrometry as the proteins Nucleophosmin, Histone H1.5, HMGB1, hnRNP-
C1/C2, hnRNP-K, and PABP2 (Fig. 4C). All of them have a nuclear distribution and known phosphorylation 
sites. Validation of those identified targets is being carried out by comparing the amounts of the identified 
proteins in the phosphoprotein-enriched fraction from RA-treated and control cells (Fig. 4D), their shift 
towards acidic pI on 2D-Western blots (Fig. 4E-H) and by immunoprecipitation with antibodies against 
phosphorylated amino acids (Fig. 4I and 4J). These results suggest that RA-induced rapid phosphorylation 
may be involved in chromatin remodelling and mRNA processing, splicing, transport and/or translation.  
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The fact that a Nuclear Receptor as RAR is involved in signalling actions normally initiated at plasma 
membrane results a paradox. A chimerical receptor was produced by fusing c-Src myristylation signal to the 
N-terminal end of RARα. This Myr-RARα is mainly located in the nucleus, but could be detected in the 
plasma membrane at significative levels (Fig. 2A). Transfection of Myr-RARα chimerical receptor to MEF-
RAR(abγ)L-/L- or COS-7 cells resulted in strong activation of PI3K/Akt, that nevertheless could be detected in 
the absence of RA (Fig. 2B and 2C). The experiment underscores a novel role for RAR at the membrane, and 
suggests a requirement of the ligand for the location of RAR at the plasma membrane, that could be 
overcome by ectopically targeting of the receptor to the membrane. We have examined the intracellular 
location of RAR. Attempts to show the presence of RAR in plasma membrane from SH-SY5Y or NIH-3T3 cells 
by immunofluorescent confocal microscopy or by using a fluorescent GFP-RARα fusion protein failed (data 
not shown). In conventional biochemical cell fractionation experiments performed with NIH-3T3 cells, a 
ligand-induced redistribution of RARγ towards plasma membrane fractions could be detected by western 
blot immunodetection (Fig. 2D). Similar fractionation experiments were performed with SH-SY5Y. Although 
RAR could not be detected in plasma membrane fractions by direct Western blot immunodetection, a ligand 
induced increase in the presence of p85-RARα complexes could be observed by immunoprecipitation (Fig. 
2E). The experiments suggest the idea of a ligand-induced translocation of a signaling complex including 
RAR and p85-PI3K to the plasma membrane, could be involved in PI3K activation by RA.  
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RA treatment results in rapid phosphorylation of well-known targets of Akt, such as mTOR and the 
ribosomal kinase p70S6 (Fig. 3A). Phosphorylation of mTOR and p70S6 kinase was detected after 10 
minutes of treatment. In addition, these phosphorylations did not occur in the presence of LY294002 
(LY), a PI3K inhibitor, demonstrating its dependence from Akt activation. We have also considered the 
phosphorylation of proteins which are likely targets of RA non-genomic actions according to the 
scientific literature, such as transcription factor CREB (Fig. 3B) and histone H3 (Fig. 3C). CREB was 
rapidly phosphorylated in presence of RA; and Ser10 of H3, whose phosphorylation is associated with 
transcriptional regulation, was clearly phosphorylated only 5 minutes after RA treatment. Both 
phosphorylations showed a biphasic profile typical of kinase signalling.  
Akt activation in response to a short-time RA treatment produces a rapid phosphorylation of 
downstream substrates, as it is shown in western-blots using an antibody that specifically recognizes 
the Akt phosphorylation domain. In nuclear extracts (Fig. 3D), an increase of phosphorylation was 
detected in a double band of approximately 32,5 KDa, and in other around 62 KDa. Similarly, we have 
performed a two-dimensional western blot with nuclear extracts (Fig. 3E) to identify the individual 
proteins spots that increased its phosphorylation as a consequence of RA treatment during 30 minutes. 
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